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Opinion statement
Idiopathic anaphylaxis is a rare life-threatening disorder with symptoms similar to other
forms of anaphylaxis. There is lack of a robust evidence base underpinning the treatment
of anaphylaxis and even less so for idiopathic anaphylaxis. Much of the evidence therefore
comes from relatively small case series and expert opinion. Idiopathic anaphylaxis is a
diagnosis of exclusion, requiring a thorough history and careful diagnostic work-up
investigating possible triggers and underlying predisposing factors. Key diagnostic tests
include skin-prick testing, tests for specific-IgE, component-resolved diagnostics, and in
some cases for allergen challenge tests. Other recognized causes of anaphylaxis, such as
foods, medications, insect stings, latex, and exercise, should all be considered, as should
differential diagnoses such as asthma. While the cause of idiopathic anaphylaxis remains
unknown, prompt treatment with intramuscular epinephrine (adrenaline) administered
into the anterolateral aspect of the thigh is associated with good prognosis. There may
also be a role for H1-antihistamines and corticosteroids as second-line agents. Patients
need to be carefully monitored for signs of deterioration and/or a possible protracted or
biphasic reaction. Patients with frequent episodes of anaphylaxis (e.g., six or more
episodes/year) should be considered for preventive therapy, which may include cortico-
steroids, H1- and H2-antihistamines, and, in some cases, mast cell stabilizers such as
ketotifen. Alternative immune-suppressants (e.g., methotrexate) and anti-IgE may rarely
also need to be considered. In many cases, the frequency of anaphylaxis declines such that
regular use of corticosteroids can be discontinued after 9–12 months. Pediatric patients
should be treated with similar regimens as adults, but with appropriate dose adjustments.
Patients should carry their self-injectable epinephrine and other emergency medications
at all times in order to deal with emergency situations.
Introduction
Anaphylaxis has been defined as a “…serious life-
threatening generalized or systemic hypersensitivity
reaction,” which is typically rapid in onset and asso-
ciated with skin and mucosal changes; it may in some
cases prove fatal [1••, 2••, 3••, 4••]. Idiopathic ana-
phylaxis is a rare form of anaphylaxis for which trig-
gers cannot be identified despite a detailed history
and careful diagnostic assessment [5••, 6••, 7–9].
Its manifestations are identical to other forms of ana-
phylaxis [5••, 6••, 7–9]. Idiopathic anaphylaxis was
first described by Bacal and colleagues in 1978 in a
report of 11 patients whose episodes could not be
explained [10••]. Although the actual incidence and
prevalence of idiopathic anaphylaxis are difficult to esti-
mate, it has been suggested that as of 1995 in the USA
alone, there were, since it was first described, at least
50,000 patients with idiopathic anaphylaxis [6••, 11••,
12]. According to most reports, idiopathic anaphylaxis
appears to be more common in females than in males,
with several studies indicating that over 60% of cases are
females [13, 14]. While idiopathic anaphylaxis was first
reported amongst adults, subsequent reports show that it is
a condition thatmay affect people of all ages, although it is
more common in adults than in children [15–18].
Diagnosis
As the name indicates, the etiology of idiopathic anaphy-
laxis remains uncertain—it is therefore a diagnosis of
exclusion [5••, 6••, 7–9]. The diagnosis should only be
made after a very thorough clinical history, physical ex-
amination, and diagnostic testing to exclude both possi-
ble triggers for anaphylaxis and possible differential di-
agnoses [1••, 2••, 3••, 4••, 5••, 6••, 7–9]. Food is the
most common trigger of anaphylaxis, accounting for up
to 30% of fatal cases [1••, 2••, 3••, 4••]. The most
common foods implicated include cow’s milk, egg, soy,
peanuts, tree nuts, fish, and shellfish [1••, 2••, 3••, 4••].
In addition, other uncommon, so-called hidden food
allergens should be considered as a differential diagnosis.
An example of this is the so-called pancake anaphylactic
syndrome or oral mite anaphylaxis, which is a new syn-
drome that presents with severe allergic symptoms and
manifests after ingestion of foods made with mite-
contaminated wheat flour, particularly pancakes [19, 20].
Other known causes, such asmedications, insect stings,
latex, and exercise, should be considered as should a host
of other differential diagnoses of anaphylaxis [1••, 2••,
3••, 4••]. In exercise-induced anaphylaxis, the imme-
diate trigger of symptoms is exercise, but in some
patients, symptoms only occur if exercise occurs after
a few hours of ingesting a specific food; this is
known as food-dependent, exercise-induced anaphy-
laxis [3••, 21, 22]. The search for triggers typically
includes skin-prick testing and tests of specific-IgE
[1•• , 2•• , 3•• , 4•• ] and may also include
component-resolved diagnostics [22] and challenge
testing. Galactose-alpha-1,3-galactose should be con-
sidered, particularly if there is a history of red meat
ingestion several hours before the attack [23]. Serum
tryptase levels can be very helpful in confirming the
diagnosis of anaphylaxis. Systemic disorders, which
may present with symptoms akin to anaphylaxis,
also need to be judiciously excluded, including
causes such as carcinoid syndrome, mastocytosis
and mast cell activation syndromes (MCAS), and
pheochromocytoma [1••, 2••, 3••, 4••]. Mast cell-
derived mediators can, for example, be helpful if
considering the diagnosis of MCAS [24], and C4
(and in some cases C1inh) concentrations can be
helpful if considering a diagnosis of hereditary an-
gioedema [25].
Clinical features and classification
Idiopathic anaphylaxis presents clinically as anaphylaxis of
unknown etiology [1••, 2••, 3••, 4••, 26••]. It is a multi-
system disorder that may present with a number of symp-
toms and signs including hives, urticaria, diarrhea,
vomiting, and angioedema; crucial to the diagnosis of
anaphylaxis however is the presence of respiratory and/or
cardiovascular compromise, which may present as cough,
wheeze, dyspnea and tachycardia, light-headedness, and
shock [1••, 2••, 3••, 4••]. Idiopathic anaphylaxis can be
classified according to the frequency andmanifestations of
attacks [5••, 6••, 7–9]. For example, patients experiencing
six or more episodes per year or two or more episodes in
2 months may be classified as idiopathic anaphylaxis-
frequent, while those experiencing fewer episodes can be
classified as idiopathic anaphylaxis-infrequent [5••, 6••,
7–9]. Classifications by manifestations of symptoms are
idiopathic anaphylaxis-generalized and idiopathic
anaphylaxis-angioedema [5••, 6••, 7–9, 11••]. Patients
with the generalized form may experience symptoms of
hypotension, gastrointestinal upset, bronchospasm, or car-
diovascular collapse, whereas anaphylaxis-angioedema pa-
tients experience angioedema or urticaria with upper
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airway compromise (resulting from laryngeal, pharyngeal,
and/or tongue edema) [5••, 6••, 7–9, 11••]. These two
classification approaches are combined into four categories
to form a summary diagnosis: idiopathic anaphylaxis-
generalized-frequent, idiopathic anaphylaxis-generalized-
infrequent, idiopathic anaphylaxis-angioedema-frequent,
and idiopathic anaphylaxis-angioedema-frequent [5••,
6••, 7–9, 11••].
Treatment
Despite the uncertainty of its etiology, idiopathic anaphylaxis is now a well-
recognized entity which, if appropriately treated, is associated with a good prog-
nosis [5••, 6••, 7–9, 26••]. For acute attacks, intramuscular epinephrine in a dose
of 0.01 mg/kg of a 1:1000 (1 mg/mL) solution to a maximum of 0.5 mg in adults
and 0.3 mg in children [1••, 2••] is the first-line agent. This is followed by
provision of emergency care for patients for continued treatment and monitoring
[5••, 6••, 7, 9, 11••]. There may also be a role for corticosteroids and H1-
antihistamines, which can be given either orally or parenterally [1••, 2••, 3••, 4••,
5••, 6••, 7–9, 26••].
All patients with a diagnosis of idiopathic anaphylaxis should be instructed
in the management of an acute episode. This primarily involves early recogni-
tion of the condition and the prompt use of epinephrine. Patients/carers should
be prescribed and instructed in the use of an epinephrine auto-injector and
encouraged to carry it with them at all times along with an H1-antihistamine
and corticosteroids [1••, 2••, 3••, 4••]. This advice is best communicated
through a written and/or electronic self-management plan [27].
Longer-term management of patients with idiopathic anaphylaxis is primarily
determined by the frequency and severity of episodes and is initiated on an
individual basis. There are no standard treatment regimens for this condition and
limited robust research has been conducted. Treatments are based on case series,
observations, and expert opinion. The algorithm developed by Patterson [26••]
and colleagues and subsequently enhanced by others [6••, 7, 28••] has proven
useful for the management of idiopathic anaphylaxis. Patients with frequent
episodes requiremaintenance therapy, which includes 40–60mg daily prednisone
and an H1-antihistamine in the form of 10 mg cetirizine, 25–50 mg hydroxyzine,
25–50mg diphenhydramine, or 180mg fexofenadine [5••, 6••, 7, 9, 11••, 26••].
Steroids are typically not required in those with less frequent anaphylaxis attacks.
Pharmacologic treatment
Classical pharmacologic treatment options for the management of idiopathic ana-
phylaxis include epinephrine, H1-antihistamines, and glucocorticoids; each will be
considered in turn below [5••, 6••, 7, 9, 11••]. Other treatments sometimes used
include H2-antihistamines, mast cell stabilizers, anti-leukotrienes, and anti-IgE. In
clinical practice, these treatments may be used ahead of regular use of steroids to
minimize the side effects associated with long-term use of systemic steroids.
Epinephrine
Epinephrine is the first-line treatment option used for the management of acute
anaphylactic attacks [1••, 2••, 3••, 4••]. It is potentially life-saving given that it has
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both alpha- and beta-adrenergic vasoconstrictor effects in most body organs and is
able to both relieve airway obstruction resulting frommucosal edema and reverse
hypotension/shock through its ionotropic and chronotropic effects [1••, 2••, 3••,
4••]. Further, epinephrine decreases mediators released from the mast cells and
basophils [29]. Epinephrine should be promptly administered once symptoms of
anaphylaxis are confirmed [1••, 2••, 3••, 4••]. It should be injected intramuscu-
larly at a dose of 0.01 mg/kg of a 1:1000 (1 mg/mL) solution, to a maximum of
0.5 mg in adults and 0.3 mg in children, into the anterolateral aspect of the thigh.
This should be repeated every 5–15 min, if necessary; most patients respond after
one or two doses [1••, 2••, 3••, 4••, 5••, 6••, 7, 9, 11••]. It is generally
recommended that epinephrine should be administered in a supine position
unless there is respiratory compromise when the patient should remain seated
[1••, 2••, 3••, 4••, 11••].
Training devices are readily available and online videos can be used to
instruct patients on how to use their auto-injector (e.g., www.youtube.
com/watch?v=tjILFYPE3Uw; www.youtube.com/watch?v=HF5a2j7mHr8).
Emergency medications should be regularly checked to ensure they have
not expired [1••, 2••, 3••, 4••]. Patients/carers may benefit from an
anaphylaxis management plan which can also be shared with school,
work, etc. [30] with clear written instructions of how to manage an acute
attack [1••, 2••, 3••, 4••]. It is important to clearly record the diagnosis
in the patient’s notes and wearing emergency jewelry (e.g., a MedicAlert
bracelet) should be encouraged [1••, 2••, 3••, 4••] so as to alert first-
responders to administer epinephrine. Patients with idiopathic anaphy-
laxis may need special consideration and careful management of their
condition during the perioperative period [1••, 2••, 3••, 4••]. Common
side effects of epinephrine include dizziness, palpitations, and tachycardia
[11••]. In some cases, failure to promptly administer epinephrine has
been associated with an increased risk of particularly severe attacks and/or
death [1••, 2••, 3••, 4••, 11••].
Glucocorticoids
The key glucocorticoid used for the treatment of idiopathic anaphylaxis is
prednisone [5••, 6••, 7, 9, 11••]. Prednisone (40–60 mg) is often used
following the administration of epinephrine to treat an attack [5••, 6••,
7, 9, 11••]. For those with frequent attacks, a maintenance therapy is
recommended at a dose of 40–60 mg daily for at least 1 week or until
symptoms subside [5••, 6••, 7, 9, 11••]. Once symptoms are controlled,
alternate-day intake of prednisone at the same dose that controlled the
symptoms is given and the dose is decreased by 5–10 mg each month
[5••, 6••, 7, 9, 11••]. With this regimen, most patients discontinue
prednisone after 9–12 months, and studies indicate that this treatment
substantially decreases the frequency and recurrent life-threatening epi-
sodes in idiopathic anaphylaxis patients [5••]. After discontinuation of
prednisone, patients may require to continue daily H1-antihistamines
[5••, 6••, 7, 9, 11••, 13]. About 20% of patients with frequent idiopathic
anaphylaxis may fail to wean from prednisone; these are thus considered
as corticosteroid-dependent idiopathic anaphylaxis [11••]. A prolonged
regimen of prednisone is often required for these patients [5••, 6••, 7, 9,
Food Allergy (M Sánchez-Borges, Section Editor)
11••]. Glucocorticoids are associated with long-term side effects, includ-
ing type 2 diabetes, glaucoma, osteopenia, and psychosis. Caution should
be exercised in using them in patients with diabetes, osteoporosis, and
hypertension and elderly patients [11••]. Alternative treatments have
been tried with some success in order to avoid the long-term use of
steroids [1••, 2••, 3••, 4••, 5••, 6••, 7, 9, 11••]. These are discussed
below.
H1- and H2-antihistamines
H1-antihistamines are often used in the management of acute attacks of
anaphylaxis where they may help to relieve cutaneous symptoms. They
may also be used in longer term as a preventive approach in those with
idiopathic anaphylaxis [5••, 6••, 7, 9, 11••]. H1-antihistamines used for
idiopathic anaphylaxis include the first-generation hydroxyzine 25–50 mg
and diphenhydramine 25–50 mg and the second-generation fexofenadine
180 mg and cetirizine 10 mg [6••, 7, 11••]. When used, each of these H1
blockers is used once or twice daily in the stated doses. The second-
generation H1 blockers are preferred to the first-generation types as
second-generation H1 blockers allow for selective antagonism of periph-
eral histamine H1 receptors and do not cause sedation as do the first-
generation H1 blockers [6••, 7, 11••]. Side effects associated with the use
of H1-antihistamines may include diarrhea, dizziness, headaches, and
dyspepsia [11••]. They should be used with caution in patients with renal
insufficiency [6••, 7, 11••]. Caution should also be exercised to ensure
that sedating H1-antihistamines are not used [31]. For long-term man-
agement, it is recommended to use a combined regimen of steroids and
H1-antihistamines and there is evidence that up to 50% of patients go into
remission after completing the recommended regimen [6••, 7, 11••].
Patients whose symptoms are not controlled with an H1-antihistamine
may benefit from addition of H2-antihistamines [32].
Emerging therapies
Omalizumab
Omalizumab is a humanized monoclonal antibody that recognizes and binds
to the Fc portion of the IgE molecule, thus blocking IgE binding to mast cells
and basophils [33–36]. It is a recognized treatment option for chronic, mod-
erate, and severe persistent allergic asthma [37] and has also been shown to play
important therapeutic role in other IgE-mediated conditions such as seasonal
and perennial allergic rhinitis and chronic idiopathic urticaria [38–40]. Re-
cently, in a series of case studies, omalizumab has been used to treat idiopathic
anaphylaxis [33–36]. Idiopathic anaphylactic patients administered 300–
375 mg dose of omalizumab once every 2 to 4 weeks, after corticosteroid and
antihistamine treatments did not reduce the frequency of attacks, were found to
be without any anaphylactic episodes in about 6–12 months of using
omalizumab [33–36]. This is however an emerging therapy in the context of
idiopathic anaphylaxis as it has only been demonstrated in a few cases.
Omalizumab is a very expensive treatment regimen and there are current
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concerns that it can also in some cases cause anaphylaxis; therefore, patients
receiving it require a period of observation after the injections [11••].
Other agents
Ketotifen, an H1-antihstiamine and mast cell stabilizer, has been shown to be
effective in reducing or terminating the dose of prednisone in corticosteroid-
dependent idiopathic anaphylaxis patients, although it has been shown to also
cause severe sedation [6••, 11••, 41] and weight increase in children [42].
Other second-line alternatives that may be steroid-sparing include anti-
leukotrienes and oral cromolyn or oral albuterol [1••, 2••, 3••, 4••, 11••].
Pediatric considerations
Pediatric idiopathic anaphylactic patients should be classified and treated with
similar regimens as adults but with dose adjustments for steroids, epinephrine,
and antihistamines [2••]. Omalizumab is licensed for use in those 12 years and
older [33–36].
Conclusions
Since it was first described 40 years ago, it has been possible to identify the
trigger factor in a small proportion of those who previously would have been
diagnosed as having idiopathic anaphylaxis. It remains a diagnosis of exclusion,
which if appropriately treated is associated with a good prognosis. Self-
injectable epinephrine should be promptly administered intramuscularly and
plans should then bemade to transfer patients to an emergency department for
monitoring. Repeated doses of epinephrine can be administered every 5–
15 min, if necessary. Preventive approaches for those with frequent episodes
include regular use of prednisone and non-sedating H1-antihistamines.
Ketotifen, anti-leukotrienes, and omalizumab may all need to be considered to
reduce the frequency of attacks and/or reduce the steroid load. Similar regimens
used for treatment of idiopathic anaphylaxis in adults can also be used in the
pediatric population although with appropriate adjustments of the doses of
steroids, epinephrine, and antihistamines. It is hoped that further advances into
the epidemiology and mechanisms of anaphylaxis will help to reduce the
numbers of patients labelled as having idiopathic anaphylaxis.
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